(Q35734917)

10 August 2017

1 reference

title

Treatment of migraine headache with botulinum toxin type A. (English)

1 reference

10 August 2017

1 reference

1 reference

William J Binder

1

1 reference

10 August 2017

Andrew Blitzer

series ordinal

2

1 reference

10 August 2017

publication date

1 November 2003

1 reference

Facial plastic surgery clinics of North America

10 August 2017

published in

1 reference

10 August 2017

volume

11

1 reference

10 August 2017

issue

4

1 reference

10 August 2017

page(s)

465-475

1 reference

An update on the epidemiology of migraine

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1064-7406%2803%2900076-2

7 January 2021

Population variation in migraine prevalence: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1064-7406%2803%2900076-2

7 January 2021

Prevalence and burden of migraine in the United States: data from the American Migraine Study II.

1 reference

https://api.crossref.org/works/10.1016%2FS1064-7406%2803%2900076-2

7 January 2021

Migraine headache in a prepaid health plan: ascertainment, demographics, physiological, and behavioral factors.

1 reference

https://api.crossref.org/works/10.1016%2FS1064-7406%2803%2900076-2

7 January 2021

Age- and sex-specific incidence rates of migraine with and without visual aura

1 reference

https://api.crossref.org/works/10.1016%2FS1064-7406%2803%2900076-2

7 January 2021

Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors

1 reference

https://api.crossref.org/works/10.1016%2FS1064-7406%2803%2900076-2

7 January 2021

Prevalence and impact of migraine

1 reference

https://api.crossref.org/works/10.1016%2FS1064-7406%2803%2900076-2

7 January 2021

Burden of migraine in the United States: disability and economic costs.

1 reference

https://api.crossref.org/works/10.1016%2FS1064-7406%2803%2900076-2

7 January 2021

Epidemiology and impact of primary headache disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1064-7406%2803%2900076-2

7 January 2021

Menstrual migraine and other hormonal aspects of migraine

1 reference

https://api.crossref.org/works/10.1016%2FS1064-7406%2803%2900076-2

7 January 2021

Migraine and tension-type headache in a general population: precipitating factors, female hormones, sleep pattern and relation to lifestyle.

1 reference

https://api.crossref.org/works/10.1016%2FS1064-7406%2803%2900076-2

7 January 2021

Changes in daily hassles, mood, and sleep in the 2 days before a migraine headache.

1 reference

https://api.crossref.org/works/10.1016%2FS1064-7406%2803%2900076-2

7 January 2021

Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study

1 reference

https://api.crossref.org/works/10.1016%2FS1064-7406%2803%2900076-2

7 January 2021

The management of hyperfunctional facial lines with botulinum toxin. A collaborative study of 210 injection sites in 162 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1064-7406%2803%2900076-2

7 January 2021

Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1064-7406%2803%2900076-2

7 January 2021

Botulinum toxin type A as an effective prophylactic treatment in primary headache disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1064-7406%2803%2900076-2

7 January 2021

Selective location of acceptors for botulinum neurotoxin A in the central and peripheral nervous systems

1 reference

https://api.crossref.org/works/10.1016%2FS1064-7406%2803%2900076-2

7 January 2021

Botulinum A toxin effects on rat jaw muscle spindles

1 reference

https://api.crossref.org/works/10.1016%2FS1064-7406%2803%2900076-2

7 January 2021

Muscle afferent block by intramuscular injection of lidocaine for the treatment of writer's cramp.

1 reference

https://api.crossref.org/works/10.1016%2FS1064-7406%2803%2900076-2

7 January 2021

The effects of in vitro application of purified botulinum neurotoxin at mouse motor nerve terminals

1 reference

https://api.crossref.org/works/10.1016%2FS1064-7406%2803%2900076-2

7 January 2021

Botulinum toxin A blocks glutamate exocytosis from guinea-pig cerebral cortical synaptosomes.

1 reference

https://api.crossref.org/works/10.1016%2FS1064-7406%2803%2900076-2

7 January 2021

Characterization of the inhibitory action of botulinum neurotoxin type A on the release of several transmitters from rat cerebrocortical synaptosomes

1 reference

https://api.crossref.org/works/10.1016%2FS1064-7406%2803%2900076-2

7 January 2021

Effects of botulinum A toxin on presynaptic modulation of evoked transmitter release

1 reference

https://api.crossref.org/works/10.1016%2FS1064-7406%2803%2900076-2

7 January 2021

Ca2(+)-dependent noradrenaline release from permeabilised PC12 cells is blocked by botulinum neurotoxin A or its light chain

1 reference

https://api.crossref.org/works/10.1016%2FS1064-7406%2803%2900076-2

7 January 2021

Inhibition of neurotransmitter release by clostridial neurotoxins correlates with specific proteolysis of synaptosomal proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1064-7406%2803%2900076-2

7 January 2021

Pharmacology and immunology of botulinum toxin serotypes

1 reference

https://api.crossref.org/works/10.1016%2FS1064-7406%2803%2900076-2

7 January 2021

The neurobiology of vascular head pain

1 reference

https://api.crossref.org/works/10.1016%2FS1064-7406%2803%2900076-2

7 January 2021

10.1016/S1064-7406(03)00076-2

Identifiers

DOI

1 reference

10 August 2017

1 reference